“Overpowered” studies due to GLs [Power / Sample Size]
Hi Khaoula,
Likely. Let’s assume a 2×2 cross-over, T/R-ratio 0.95, n=12. For any CV ≤15.63% power will be >80%, for CV ≤13.39% >90%, for CV ≤9.85% >99%, etc. etc.
The lowest CVs I have seen so far were 5–7% (AUCs of valproic acid, methylphenidate). If you perform a study with a drug showing a CV of 6% in 12 subjects, power will be 99.99993%. In other words, a significant treatment effect is highly probable. See this presentation (slide 9): The red diamonds are sample sizes to reach at least 80% power. If you keep the sample size at 12 for low CVs, power will increase extremely (blue line).
BTW, the minimum sample size of 12 is arbitrary; some tables1,2 go down to 4.
❝ for minimum number of subject: it's not about possible significant treatment effect with low nuber of subject, low CV?
Likely. Let’s assume a 2×2 cross-over, T/R-ratio 0.95, n=12. For any CV ≤15.63% power will be >80%, for CV ≤13.39% >90%, for CV ≤9.85% >99%, etc. etc.
The lowest CVs I have seen so far were 5–7% (AUCs of valproic acid, methylphenidate). If you perform a study with a drug showing a CV of 6% in 12 subjects, power will be 99.99993%. In other words, a significant treatment effect is highly probable. See this presentation (slide 9): The red diamonds are sample sizes to reach at least 80% power. If you keep the sample size at 12 for low CVs, power will increase extremely (blue line).
BTW, the minimum sample size of 12 is arbitrary; some tables1,2 go down to 4.
- Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharm Ther Toxicol. 1991;29(1):1–8. PMID 2004861.
- Hauschke D, Steinijans VW, Diletti E, Burke M. Sample Size Determination for Bioequivalence Assessment Using a Multiplicative Model. J Pharmacokin Biopharm. 1992;20(5):557–61. PMID 1287202.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- minimum number of subject in bioequivalence study khaoula 2014-09-27 11:14
- minimum number of subject in bioequivalence study ElMaestro 2014-09-27 11:26
- minimum number of subject in bioequivalence study khaoula 2014-09-27 23:49
- “Overpowered” studies due to GLsHelmut 2014-09-28 01:13
- “Overpowered” studies due to GLs khaoula 2014-09-28 22:36
- “Overpowered” studies due to GLs Helmut 2014-09-29 03:51
- Scientific Validation for the Sample Size Formula mreyes 2014-11-07 19:47
- Basic maths Helmut 2014-11-07 20:09
- Basic maths mreyes 2014-11-07 20:47
- Reference for CI ⇒ MSE Helmut 2014-12-14 01:51
- Reference for CI ⇒ MSE mreyes 2015-02-19 19:50
- Failed study: power <80%! Helmut 2015-02-20 19:09
- Failed study: power <80%! mreyes 2015-02-23 17:07
- Reported 99.98%, correct 1.4% Helmut 2015-02-23 17:38
- Reported 99.98%, correct 1.4% ElMaestro 2015-02-23 17:51
- GMR ∉ AR ⇒ power <5% Helmut 2015-02-24 01:33
- GMR ∉ AR ⇒ power <5% mreyes 2015-02-24 17:34
- GMR ∉ AR ⇒ power <5% Helmut 2015-02-24 01:33
- Reported 99.98%, correct 1.4% ElMaestro 2015-02-23 17:51
- Reported 99.98%, correct 1.4% Helmut 2015-02-23 17:38
- Failed study: power <80%! mreyes 2015-02-23 17:07
- Failed study: power <80%! Helmut 2015-02-20 19:09
- Reference for CI ⇒ MSE mreyes 2015-02-19 19:50
- Basic maths Helmut 2014-11-07 20:09
- “Overpowered” studies due to GLs khaoula 2014-09-28 22:36
- “Overpowered” studies due to GLsHelmut 2014-09-28 01:13
- minimum number of subject in bioequivalence study khaoula 2014-09-27 23:49
- minimum number of subject in bioequivalence study ElMaestro 2014-09-27 11:26
